1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A

Sinopep-Allsino Bio Pharmaceutical Co., Ltd. Class A

SSSE:688076
27.20
CNY
-0.74
(-2.65%)
0.67EPS
32.62P/E
8.50BMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
0.17
0.1
2.02
1.86
2.29
3.54
3.19
3.05
4.82
5.38
6.2
6.46
Basic EPS, GAAP
-0.12
-0.5
-0.6
-0.91
0.37
0.32
0.3
0.77
0.47
0.6
0.76
1.34
1.06
0.82
Free Cash Flow per Basic Share
0.16
1.16
-2.48
-0.41
-0.55
-0.74
-1.42
0.19
-0.27
-2.06
-1.45
-2.29
-2.19
- -
Dividend per Share
0.06
0.1
0.09
0.05
0.52
0.06
0.07
0.07
0.03
0.19
0.27
0.39
0.76
1.14
Book Value per Share
0.03
-0.18
0.62
0.3
2.73
4.87
5.22
6.03
8.38
6.31
10.16
12.09
9.45
9.78
Tangible Book Value per Share
-0.17
-0.4
0.38
0.12
0.78
3.3
3.65
4.43
7.17
5.35
8.76
10.12
7.52
7.77
Basic Weighted Avg Shares
117
50
50
82
113
137
162
160
193
213
214
302
314
316
Sales/Revenue/Turnover
- -
- -
9
9
229
256
372
567
614
651
1,034
1,625
1,943
2,038
Operating Margin (%)
- -
- -
-289.75
-829.21
29.61
16.26
16.68
30.03
19.37
18.34
22.45
32.32
28.42
29.2
Depreciation Expense
3
9
10
11
19
24
42
71
85
100
136
210
318
- -
Net Income, GAAP
-14
-25
-30
-75
42
44
49
123
90
128
163
404
332
260
Effective Tax Rate (%)
- -
- -
- -
- -
26.46
- -
16.11
18.1
16.94
0.16
4.43
8.82
9.73
10.03
Profit Margin (%)
- -
- -
-343.55
-879.02
18.32
17.18
13.08
21.78
14.74
19.66
15.76
24.89
17.11
12.78
Working Capital
-150
-167
-73
-104
-101
108
-41
106
800
501
521
253
349
317
LT Debt
- -
- -
- -
- -
- -
7
54
32
3
- -
304
471
1,351
1,302
Total Equity
4
-21
73
35
321
785
839
966
1,784
1,899
2,185
2,678
3,002
3,102
Return on Invested Capital (%)
- -
- -
- -
- -
14.41
- -
4.3
10.38
5.56
6.04
6.85
11.07
7.42
6.3
Return on Capital (%)
- -
- -
- -
- -
16.54
- -
6.11
12.08
6.62
7.03
6.63
11.91
7.98
6.53
Return on Common Equity (%)
- -
- -
- -
-138.17
23.55
7.99
6.03
13.73
6.58
6.98
8.04
16.77
11.78
8.81

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,309
1,366
1,530
LT Borrowings
1,322
1,322
1,273
LT Finance Leases
29
27
29
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
316
316
316
Market Capitalization
11,915
9,188
8,502

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,512
2,487
2,627
Cash, Cash Equivalents & STI
1,030
941
957
Accounts Receivable, Net
501
531
616
Inventories
860
899
944
Total Current Liabilities
2,163
2,127
2,309
Payables & Accruals
- -
- -
- -
ST Debt
1,309
1,366
1,530
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
107.39%
28.17%
12.07%
Free Cash Flow
64.33%
110.43%
-0.61%
Net Income, GAAP
33.38%
34.49%
-17.8%
Sales/Revenue/Turnover
284.61%
29.97%
19.57%
Total Cash Common Dividend
198.68%
154.64%
101.77%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
356
476
421
373
1,625
2025
566
483
- -
416
1,943
2026
553
587
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.31
0.53
0.41
0.18
1.34
2025
0.5
0.5
- -
-0.35
1.06
2026
0.41
0.27
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.03
0.3
0.1
-0.02
0.39
2025
0.04
0.61
- -
0.06
0.76
2026
0.06
0.41
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Zi Quan Tong
Full Time Employees
2,360
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 1378 Wenyi West Road Hangzhou ZH China 311121
IPO Date
May 20, 2021
Website
sinopep.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Jiangsu Sinopep-Allsino Biopharmaceutical Co., Ltd. (688076.SS) is a leading China-based biomedical company that specializes in the research, development, production, sale, and technical services of peptide drugs, oligonucleotides, and small molecule drugs. The company operates through customized product and independently selected product businesses; its customized segment provides CDMO (Contract Development and Manufacturing Organization) services, CRO (Contract Research Organization) technical services, and technology transfer for peptides, oligonucleotides, small molecules, and conjugates including peptide-oligonucleotide conjugates (POCs), peptide-conjugated PMOs (PPMOs), and peptide-drug conjugates (PDCs); it also offers generic APIs such as semaglutide, liraglutide, oseltamivir phosphate, thymalfasin, eptifibatide, bivalirudin, octreotide acetate, lanreotide acetate, cetrorelix, fulvestrant, and inclisiran, alongside intermediate products and finished dosage form (FDF) formulation services for oral solid dosage forms and lyophilized powder injections. Founded in 2009, the company is headquartered in Hangzhou, Zhejiang Province, China, with key manufacturing sites in Lianyungang (Jiangsu), Jiande, Hainan, and Hangzhou (including the Xiasha site via subsidiary Apextide); it serves pharmaceutical and biotechnology clients in domestic China and overseas markets, targeting high-demand therapeutic areas such as diabetes, cardiovascular diseases, oncology, antiviral treatments, and assisted fertility. Recent developments include the establishment of a strategic joint venture with Vazyme (688105.SH) in 2025 to advance synthetic biology applications across biopharmaceuticals, animal healthcare, and agriculture, with Sinopep holding majority control; the launch of its fourth-generation large-scale peptide production facility (Workshop 601) at Lianyungang; FDA acceptance of a DMF for inclisiran API by subsidiary Apextide in April 2025 and successful completion of an FDA GMP inspection at Apextide; receipt of the first FDA Adequate Letter for semaglutide in 2024; achievement of Brazilian ANVISA GMP certification for the Lianyungang facility; a strategic cooperation agreement with Spraying Systems Co.; and EcoVadis sustainability certifications, including a Silver Rating for the ApexTide Hangzhou site and Bronze Medals for Jiande and Lianyungang sites.